Jonathan J. Katz

Katz’s notable transactions include representing:

• PepsiCo in its strategic partnership with Celsius, including a $585 million PIPE investment in Celsius and sale to Celsius of Rockstar Energy in the U.S. and Canada;
• Disney in its $85 billion acquisition of 21st Century Fox, overcoming an interloper bid by Comcast to its original $66 billion agreement; the $10.6 billion sale of the Fox Regional Sports Networks to Sinclair; the $3.47 billion sale of its interest in the YES Network to an investor group including the Yankees and Sinclair; ESPN’s pending acquisition of NFL Network and other media assets from the NFL in exchange for a 10% equity stake in ESPN; the pending combination of its Hulu + Live TV business with Fubo; ESPN’s proposed joint venture with Fox and Warner Bros. Discovery to launch Venu Sports; and the sale of Fox TeleColombia & Estudios TeleMexico to ViacomCBS;
• Flowserve in its proposed $19 billion merger of equals with Chart Industries;
• Paramount’s special committee in the $28 billion merger with Skydance;
• CymaBay Therapeutics in its $4.3 billion acquisition by Gilead Sciences;
• Robinhood in its IPO and its $300 million acquisition of TradePMR;
• CardWorks in its acquisition of Ally’s credit card business;
• H.J. Heinz Company in its $60 billion merger with Kraft Foods Group to create The Kraft Heinz Company;
• Viatris in its divestitures totaling $6.94 billion in value, including the $3.335 billion combination of its biosimilars portfolio with Biocon Biologics and the divestitures of its Over‑the‑Counter, Women’s Healthcare and Active Pharmaceutical Ingredients businesses, its $750 million acquisitions of Oyster Point and Famy Life Sciences and its global research and development collaboration with Idorsia;
• Mylan in its $50 billion combination with Upjohn, a division of Pfizer, to form Viatris, its proposal to acquire Perrigo in a transaction valued at approximately $35 billion, its $9.9 billion acquisition of Meda and its $5.6 billion inversion acquisition of Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business;
• Canadian National Railway in its proposed $33.6 billion combination with Kansas City Southern;
• Johnson & Johnson in the IPO and separation of Kenvue, its $30 billion acquisition of Actelion, its $16.6 billion acquisition of Abiomed, its $6.5 billion acquisition of Momenta, its $4.325 billion acquisition of Abbott Medical Optics, its $3.4 billion acquisition of Auris Health, the $2.8 billion sale of its Advanced Sterilization Products business to Fortive, the $2.1 billion sale of its LifeScan business to Platinum Equity and the $1.045  billion sale of its Codman Neurosurgery business to Integra LifeSciences;
• IBM in multiple transactions, including its acquisition of Accelalpha, its acquisition of Polar Security, its acquisition of StepZen, its acquisition of Octo from Arlington Capital, its acquisition of Databand.ai, its acquisition of Randori and the sale of its healthcare and data analytics assets, part of the Watson Health business, to Francisco Partners;
• Viacom’s transaction committee in the $30 billion merger with CBS;
• Biogen in its $7.3 billion acquisition of Reata Pharmaceuticals and its $1.25 billion settlement and license agreement with Forward Pharma;
• The Snyder family in the $6.05 billion sale of the NFL’s Washington Commanders to a partnership led by Josh Harris;
• Cameron International in its $15 billion sale to Schlumberger and in the creation of the OneSubsea joint venture with Schlumberger;
• Starwood Hotels in its $13.3 billion sale to Marriott International;
• Northrop Grumman in its $9.2 billion acquisition of Orbital ATK and the $3.4 billion sale of its federal IT and mission support business to Veritas Capital;
• AveXis in its $8.7 billion acquisition by Novartis;
• Brookfield and its affiliates in Brookfield Renewable’s strategic partnership with Cameco to acquire Westinghouse for $8 billion, the $3.8 billion acquisition of a controlling stake and $1.58 billion acquisition of the remaining stake in TerraForm Power and the $1.3 billion acquisition of TerraForm Global;
• Alere in its $8 billion sale to Abbott Laboratories;
• GW Pharmaceuticals in its $7.2 billion acquisition by Jazz Pharmaceuticals;
• Atlas Air in its $5.2 billion acquisition by an investor group led by Apollo;
• BDT Capital Partners in connection with the ERISA aspects of structuring BDT Capital Partners Fund II and its related parallel funds and the $5.2 billion fundraising of capital commitments from over 100 investors;
• Ashland in its $3.2 billion acquisition of International Specialty Products;
• Valvoline in the $2.65 billion sale of its Global Products business to Aramco;
• The Aquarion Water Authority in its pending $2.4 billion acquisition of Aquarion Water Company from Eversource Energy;
• Jones Group in its $2.2 billion sale to Sycamore Partners;
• Novartis in its $2.1 billion acquisition of Endocyte;
• Daily Mail and General Trust in the £1.425 billion sale of RMS to Moody’s;
• US Foods in its $1.8 billion acquisition of SGA Food Group;
• New Media in its $1.4 billion acquisition of Gannett;
• UTi Worldwide in its $1.35 billion sale to DSV;
• CommScope in its $1 billion investment from The Carlyle Group as part of CommScope’s $7.4 billion acquisition of ARRIS;
• Route Mobile and its founding shareholders in the ₹59.22 billion sale of a majority stake in Route Mobile to Proximus Group; and
• Unilever in its acquisition of a majority stake in Nutrafol.